SOLICITATION NOTICE
66 -- Extracellular Flux Analyzer
- Notice Date
- 8/20/2015
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-HI-2015-219-CDB
- Archive Date
- 9/19/2015
- Point of Contact
- Chris Bocus, Phone: 3014027888
- E-Mail Address
-
chris.bocus@nih.gov
(chris.bocus@nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- DESCRIPTION: (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This acquisition is set aside for small businesses only. (ii) The solicitation number is HHS-NIH-NHLBI-CSB-HI-2015-219-CDB and the solicitation is issued as a request for quote (RFQ). Offerors shall submit their proposals no later than 3:00 p.m. Eastern Standard Time(EST) on Friday, September 4, 2015. Eastern Standard Time (EST). (iii) The solicitation document, the incorporated provisions and clauses are those in the Federal Acquisition Circular 2005-83, effective August 3, 2015. (iv) The associated North American Industry Classification System (NAICS) code for this procurement is 334516 and the small business size standard is 500 employees. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. PURPOSE: The purpose of this requirement is to procure an Extracellular Flux Analyzer for the Center for Molecular Medicine, part of the National Heart, Lung and Blood Institute. (v) Background: The mission of the NHLBI Division of Intramural Research (DIR) is to perform robust scientific and clinical research leading to a better understanding of biology and clinical pathology. To attain this goal, we have built a strong basic science foundation and coupled it closely with innovative technology development and outstanding clinical research both at the NIH Clinical Center and in partnership with local hospitals. The purview of DIR's research is broad, encompassing investigations into the basic principles of molecular, cellular, and organ-level biology and their relationship to disease. Some current areas of fundamental interest include single molecule structure; protein assembly; molecular and cell biology; cell signaling and motility; membrane trafficking; physiology; systems biology; engineering and technology development. Insights into disease mechanisms derived from basic studies form the basis for translational research into new diagnostic and therapeutic approaches. DIR investigators also conduct concept-based clinical studies in the areas of interventional and surgical cardiology; pulmonary medicine; sickle cell anemia; bone marrow transplant; and hematologic disorders. The studies performed in the Center for Molecular Medicine (CMM) focus on the concept that many diseases have at their root a small number of molecular mechanisms, which if properly understood, could be efficiently targeted with appropriate therapeutics. Researchers in the Center for Molecular Medicine study diseases ranging from atherosclerosis, aging, metabolism and neurodegeneration by conducting biomedical research directed at defining molecular mechanisms underlying human disease, developing a range of animal and cell based models of human diseases and implementing mechanism-driven clinical studies designed to provide insight regarding underlying disease mechanisms or test proof-of principle therapeutic approaches. The acquisition of an Extracellular Flux Analyzer that is compatible with the existing analyzer is required to continue its current research efforts. The contractor will provide one (1) Seahorse Biomedical XFe96 Extracellular Flux Analyzer including the following: • 102342-100 XFe24 FluxPak mini (2) • 103015-100 XF Cell Mito Stress Test Kit • 103020-100 XF Glycolysis Stress Test Kit • 102353-100 XF Base Medium • TRAINING XF Training - one 2-day session • One-year XFe96 Analyzer Warranty • XF Palmitate-BSA FAO Substrate Shipping and handling must be included in the total price quote. (vi) Period of Performance: Delivery schedule will negotiated at award. (vii) The provision FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition and is hereby incorporated by reference. (viii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition and is hereby incorporated by reference. (ix) In accordance with FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items, Offerors must complete annual representations and certifications on-line at https://www.sam.gov/portal/public/SAM/. (x) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items, applies to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) and assigned rating does not apply to this acquisition. BRAND NAME: The requested equipment must be Seahorse Bioscience Inc. certified equipment and the offeror must be a certified re-seller of Seahorse Bioscience Inc. equipment. Offerors shall submit their quotations no later than 3:00 p.m. Eastern Standard Time (EST) on Friday, September 4, 2015. The proposal must reference the RFP Number: HHS-NIH-NHLBI-CSB-HI-2015-219-CDB. All responsible offerors may submit a proposal, which if timely received, shall be considered by the agency. This acquisition is set-aside for SMALL BUSINESSES. Proposals can be emailed to the Contract Specialist, Chris Bocus at chris.bocus@nih.gov; Quotations shall not be deemed received by the Government until the quotation is entered into the e-mail address inbox set forth above. Faxed proposals will NOT be accepted. All quotes shall contain the following: 1. Name of Contracting Organization; 2. Contract Number/RFP Number (for subcontracts, provide the prime contract number and the subcontract number); 3. Contract Type; 4. Total Contract Value and Discounts; 5. Description of Requirement; 6. Contracting Specialist's Name and Telephone Number; 7. North American Industry Classification System (NAICS) Code; and 8. DUNS Number.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-HI-2015-219-CDB/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03847858-W 20150822/150820235834-bf1530f797259a4f8a43498bcb871090 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |